Before these were being given to children but adults were on shot 2 or 3, our newborn department was full of unseasonal RSV cases that had to stay hospitalized. It made its way through all of the hospitals for the staff too with long-lasting cases.
Before these were being given to children but adults were on shot 2 or 3, our newborn department was full of unseasonal RSV cases that had to stay hospitalized. It made its way through all of the hospitals for the staff too with long-lasting cases.
Good thinking. I'd be curious to see RSV data by age between 2021 and 2022, because newborns in 2021 might have been the canary in the coalmine due to getting everything from breast milk, which the older children at that point wouldn't have gotten.
In addition to milk, if the baby was being held by someone who recently got it, shedding could be a contributor - this article for example shows that researchers have known for decades that adeno-based carriers shed:
2003 Wang F. et al.: Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens. doi: 10.1089/10430340360464688.
Before these were being given to children but adults were on shot 2 or 3, our newborn department was full of unseasonal RSV cases that had to stay hospitalized. It made its way through all of the hospitals for the staff too with long-lasting cases.
It's been proven there was indeed vaccine shedding... so I have to wonder could this be why?
Good thinking. I'd be curious to see RSV data by age between 2021 and 2022, because newborns in 2021 might have been the canary in the coalmine due to getting everything from breast milk, which the older children at that point wouldn't have gotten.
In addition to milk, if the baby was being held by someone who recently got it, shedding could be a contributor - this article for example shows that researchers have known for decades that adeno-based carriers shed:
2003 Wang F. et al.: Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens. doi: 10.1089/10430340360464688.